flow trial semaglutide renal outcomes 2024 Effects of With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A Prespecified Secondary Analysis Media Centre | EASD
Description
In the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) outcomes trial, adults with overweight or obesity and established cardiovascular disease but without diabetes had fewer major adverse cardiovascular events with semaglutide than with placebo 14,15
Your provider will guide initial dosing, monitor tolerance, and adjust the schedule based on your response
Therefore, managing type 2 diabetes extends beyond glycemic control, making cardiovascular safety a crucial consideration when selecting an anti-diabetic agent
We provide a program designed to promote proper eating habits and balanced blood sugar levels while utilizing the Semaglutide medication
At 26 weeks, oral semaglutide was superior to placebo in decreasing HbA 1c (estimated mean change of -10 percentage point (SE 01
